Psychedelic substances such as psilocybin, LSD, and ayahuasca analogues are increasingly used in neuroscientific research to understand how the brain constructs the sense of self. Functional MRI studies from 2023-24 demonstrate that psychedelics reduce activity in the brain’s default mode network (DMN), a neural circuit implicated in self-referential thought and consciousness (The Hindu, 2024). This neural modulation challenges traditional models of a fixed, unitary self and offers novel perspectives on consciousness and identity formation. Clinically, over 30 global trials have shown psilocybin’s efficacy in treatment-resistant depression, with remission rates reaching 60% (JAMA Psychiatry, 2023). India’s regulatory framework, governed by the Narcotic Drugs and Psychotropic Substances Act, 1985 and the Drugs and Cosmetics Act, 1940, currently restricts psychedelic research, limiting clinical innovation despite growing international momentum.

Neuroscience of Psychedelics and Self-Perception

Psychedelics act primarily on the serotonin 2A receptor, disrupting the DMN’s activity, which is associated with the brain’s baseline self-referential processing (The Hindu, 2024). Reduced DMN connectivity correlates with ego dissolution experiences, indicating a temporary alteration in self-boundaries. A 2023 NIMHANS pilot study on ayahuasca analogues involving 20 volunteers reported measurable changes in self-perception metrics, confirming psychedelics’ capacity to modulate self-awareness in controlled settings. These findings support a model of the self as a dynamic neural construct rather than a static entity.

• DMN suppression by psychedelics linked to decreased self-focus and increased present-moment awareness.
• Psilocybin-assisted therapy shows promise for treatment-resistant depression and anxiety disorders.
• Neuroplasticity enhancement observed post-psychedelic exposure suggests potential for long-term therapeutic effects.

Legal and Regulatory Framework Governing Psychedelics in India

The Narcotic Drugs and Psychotropic Substances Act, 1985 defines psychotropic substances under Section 2(vi) and criminalizes unauthorized manufacture, possession, and use under Section 27. Psychedelic substances fall within this ambit, restricting their legal use. Clinical trials involving psychedelics must comply with the Drugs and Cosmetics Act, 1940, particularly Schedule Y, which governs trial protocols and safety standards. The Mental Healthcare Act, 2017 mandates informed consent (Sections 18 and 21) and patient rights, critical for ethical psychedelic-assisted therapies. India is also bound by the UN Convention on Psychotropic Substances, 1971, which influences domestic narcotics control policies.

• NDPS Act restricts psychedelic substances, posing challenges for research and therapy.
• Clinical trials require ICMR approval and adherence to Schedule Y guidelines.
• Mental Healthcare Act ensures patient autonomy and safeguards in psychiatric interventions.

Economic Dimensions of Psychedelic Research and Therapy

The global psychedelic drugs market was valued at USD 3.9 billion in 2023, with a compound annual growth rate (CAGR) of 16.3% projected through 2030 (Grand View Research, 2024). India’s pharmaceutical sector, valued at USD 50 billion, is beginning to explore psychedelics under the Department of Biotechnology’s Indigenous Neurotechnology Mission (INBT), which allocated INR 100 crore for 2023-2025. Mental health disorders, including depression and anxiety, impose a global economic burden estimated at USD 1 trillion annually (WHO, 2022). Psychedelic-assisted therapies, costing between USD 1,000-3,000 per session in the US, offer cost-effective alternatives to chronic pharmacotherapy (MAPS, 2023).

• Potential to reduce long-term mental health treatment costs through durable remission.
• Limited Indian funding (<5%) allocated to psychedelic research (ICMR Annual Report, 2023).
• Opportunity for India’s pharma sector to innovate in neuropsychiatric therapeutics.

Key Institutions Driving Psychedelic Research and Regulation

India’s research ecosystem includes the Department of Biotechnology (DBT) funding neuroscience and psychedelic studies, and the Indian Council of Medical Research (ICMR) overseeing ethical approvals. The National Institute of Mental Health and Neurosciences (NIMHANS) leads clinical research on psychedelics and brain function. Internationally, the US Food and Drug Administration (FDA) has granted psilocybin a 'Breakthrough Therapy' designation since 2018, accelerating clinical trials and commercial development. The Multidisciplinary Association for Psychedelic Studies (MAPS) is a key global NGO advocating for research and policy reform.

• DBT’s INBT mission supports interdisciplinary neurotechnology and psychedelic research.
• ICMR ensures compliance with ethical standards and clinical trial regulations.
• NIMHANS conducts pioneering clinical and neuroimaging studies on psychedelics.
• FDA’s regulatory flexibility contrasts with India’s restrictive environment.

Comparative Analysis: India vs United States on Psychedelic Regulation and Research

Critical Regulatory Gaps and Challenges in India

India lacks a dedicated regulatory framework specifically for psychedelic research and therapy, resulting in overlapping jurisdiction between narcotics control authorities and medical ethics committees. This fragmentation delays clinical trials and hinders integration of psychedelic therapies into mainstream mental healthcare. The NDPS Act’s broad prohibition does not distinguish between recreational abuse and controlled therapeutic use, restricting innovation. Additionally, limited funding and infrastructure constrain large-scale neuroimaging and clinical research, despite rising mental health burdens.

• Absence of clear guidelines for psychedelic-assisted therapy trials.
• Need for harmonization between NDPS Act and Drugs and Cosmetics Act provisions.
• Ethical frameworks for informed consent and patient safety require strengthening.

Significance and Way Forward

Psychedelic research is reshaping neuroscientific understanding of consciousness and selfhood, with direct implications for treating refractory mental illnesses. India must modernize its regulatory architecture to facilitate ethical clinical trials while preventing misuse. Expanding funding through DBT and ICMR can position India as a global hub for neuropsychiatric innovation. Integrating psychedelic therapies with mental healthcare services could reduce the socio-economic burden of mental disorders. Collaborative international research and policy dialogue will accelerate responsible adoption.

• Establish a dedicated regulatory framework for psychedelic research and therapy.
• Increase budgetary allocations for neuroscience and psychedelic studies.
• Develop guidelines for patient consent and safety in psychedelic-assisted therapy.
• Promote interdisciplinary collaboration between neuroscientists, clinicians, and policymakers.

Jharkhand & JPSC Relevance

• JPSC Paper: Paper 3 – Science and Technology, Mental Health Policies
• Jharkhand Angle: Rising mental health challenges in Jharkhand necessitate innovative treatment approaches; limited local research capacity mirrors national gaps in psychedelic research.
• Mains Pointer: Frame answers by linking neuroscience insights to mental health burden in Jharkhand, highlight regulatory barriers and need for capacity building in state medical institutions.